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Here we present bifunctional microparticles that bind Escherichia coli (E. coli) 
bacteria via a cell membrane constituent while also activating the classical complement 
pathway. Carboxylated polystyrene microparticles 1 µm in diameter were functionalized 
through several means with nonspecific polyclonal IgG and/or a monoclonal E. coli-
binding antibody to compare different targeting schemes to localize complement to a 
particular bacterial strain. The complement-prompting polyclonal antibody was either 
adsorbed to saturate the particle nonspecifically (Untargeted, UT), adsorbed 
nonspecifically at half-saturation in combination with the targeting antibody (Mixed 
Untargeted, MUT), or interspersed amongst crosslinker-monoclonal antibody pairs 
formed such that the antibody Fab regions project outward (MT, Mixed Targeted). 
Cytotoxicity of each particle type to its cognate, either complement-sensitive non-
pathogenic mutant E. coli J5 and wild-type pathogenic E. coli O157:H7 was evaluated, as 
was targeting affinity for anti-J5 particles and J5 bacteria. Although no type provided 
clinically-relevant cytotoxicity, notably the MUT particles were somewhat effective 
against the virulent and otherwise complement-resistant O157. Orienting the targeting 
moiety with the MT provided no benefit against either strain, and binding frequencies 
were attenuated relative to the MUT for J5 bacteria. Complement-sensitive J5 was most 
vulnerable to UT particles. In most cases, there was a correlation between increased 
cytotoxicity and the extent of IgG coverage, but this effect was generally not pronounced. 
Additional modifications to the MUT platform to more potently stimulate complement 
activation and a new base material for biocompatibility could enable its use as a sensitizer 
to be paired with antibiotics for systemic diseases such as sepsis or candidiasis.  
 
1 
CHAPTER 1: INTRODUCTION 
 
1.1 Antimicrobial Resistance and Conventional Antibiotics 
 Multidrug antimicrobial resistance (AMR) in bacteria is a universal, growing healthcare 
problem – methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile are 
well-known, but certain Gram-negative strains, such as Klebsiella pneumoniae, may resist almost 
all known antibiotics [1]. Approximately 2 million new cases of AMR emerge in the United 
States each year, contributing to more than 20,000 deaths, many of which are preventable [2, 3]. 
To counter otherwise lethal selective pressure, bacteria will continuously develop means to 
evade antibiotics or reduce their effectiveness – more than 70% of disease-causing bacteria are 
estimated to resist at least one antibiotic in common use [4]. By 2050, the WHO projects AMR 
to be responsible for more annual mortalities than cancer and diabetes [5] (Figure 1.1 A). This 
issue is exacerbated further by a reduction of novel antibiotics coming to market; the number of 
antibiotics receiving FDA approval has fallen 90% during the past three decades [6]. Of those 
currently in the clinic, few are effective against Gram-negative strains that are often extensively 
drug-resistant, namely the Enterobacteriaceae (which include Escherichia coli and Klebsiella) 
and Pseudomonas aeruginosa [7]. The pharmaceutical pipeline is also deficient, as industry has 
favored antibiotic development against methicillin-resistant Staphylococcus aureus, given the 
larger market scope and slower acquisition of resistance (Figure 1.1 B). Investment in antibiotic 
development is also less appealing given recently revised FDA stipulations to study designs 




Figure 1.1: Despite a growing public health concern, antibiotic development has not kept pace. (A) By 2050, deaths 
attributed to drug resistance in bacteria globally are estimated to supersede those of more notorious public health 
issues. Figure adapted from the Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis 
for the Health and Wealth of Nations. 2014 [9]. (B) Novel antibiotic development has fallen precipitously over the 
past several decades, likely due to fewer economic incentives. Figure from CDC. Antibiotic Resistance Threats. 
2013 [3]. 
   
 As antibiotics in clinical use are non-specific, susceptible commensal bacteria inhabiting 
the epithelial surfaces of the body (the airways, mucosa, skin, and digestive tract) are killed, 
facilitating colonization by resistant pathogenic bacteria. Not only do commensals compete with 
pathogens for nutrients, but they may release antimicrobials such as bacteriocidins or prompt 
immunostimulatory pathways, such as triggering Paneth cells in proximity to release C-type 
lectins and defensins [10, 11]. Some of these agents show considerable promise as novel 
antibiotics, and are only now being elucidated [12]. In addition, accumulating evidence 
implicates antibiotic disruption of commensal populations in chronic inflammatory bowel 
diseases [13, 14], as well as diabetes [15, 16], particularly if given in early life.  
1.2 The Complement System 
 The complement system is an integral component of the innate immune response and 
refers to a group of 30+ interacting proteins that recognize conserved molecular signatures on 
B A
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pathogens, initiating their opsonization and lysis [17-19]. The pathway bridges humoral and 
adaptive immunity, as complement mediators both recruit phagocytes and initiate adaptive 
immune responses [18, 20, 21]. The tail of each immunoglobulin class, the crystallizable 
fragment (Fc), is essential in immune priming following pathogen opsonization as it allows for 
activation of the classical complement pathway, culminating in lysis, but also recognition by 
neutrophils and macrophages [22-25].  
 The classical or antibody-mediated pathway (Figure 1.2) is activated robustly following 
the binding of the pattern recognition molecule C1q to proximal Fc regions of multiple IgG 
antibodies or a single IgM antibody [26, 27]. C1q also recognizes and binds bacteria via 
pentraxins, a class of plasma proteins that detect foreign and modified self-antigens [28]. The 
essential pentraxins of human plasma include serum amyloid P (SAP), pentraxin 3, and C-
reactive protein [28]. C1q can also directly bind to carbohydrate constituents of pathogen 
surfaces to initiate the classical pathway [29, 30]. Bound C1q then interacts in series with 
proteases C1r and C1s. The now activated C1s cleaves C4 into C4a and C4b; a reactive thioester 
on C4b is exposed such that C4b opsonizes surfaces in proximity to the point of activation. C1s 
cleaves C2 bound to this C4b, forming C2a and C2b. C2b is critical in that it forms the C3 
convertase with C4a. The C3 convertase rapidly cleaves C3 to C3a and C3b. The alternative and 
lectin-mediated pathways, though initiated via different mediators, merge at the complement 
opsonin C3b. Concurrent C3b amplification occurs due to alternative pathway activation, as 
factor B binds surface-bound C3b, forming the alternative pathway C3 convertase (C3bBb) in a 
compounding loop. C3b serves as the effector of the cytotoxic function of both pathways, as 
increased C3b binding transitions the main substrate of the convertases from C3 to C5 (C5 
convertase: C4b2a3b). A product of C5 cleavage, C5b, forms part of the terminal complement 
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complex (TCC) or the membrane attack complex (sC5b-C9). TCC forms a pore in the pathogen 
membrane, resulting in lysis [31]. Anaphylatoxins such as C3a and C5a formed during the 
cascade trigger the inflammatory response and act as phagocyte chemoattractants [32].  
 
Figure 1.2: A simplified depiction of the classical or antibody-mediated pathway of complement activation. The 
pathway is initiated by the binding of C1q to antibodies that recognize pathogen-associated molecular patterns 
(PAMPs) on the bacterium surface. A proteolytic cascade follows, in which the classical C3 convertase (C4b2b) is 
formed, resulting in C3 cleavage and C3b deposition, in addition to analyphlatoxin C3a/4a generation to spur 
phagocyte influx and downstream inflammatory responses. From these split products the classical C5 convertase 
forms (C4b2a3b), and from the cleavage of C5, C5b joins with C6-C9 to form the terminal complement complex 
(TCC). TCC forms a pore in the membrane, causing lysis. C5a, the other split product of C5, like C3a, is a potent 
stimulator of further proinflammatory signaling and phagocyte chemotaxis. Figure from [33].  
  
  The alternative and lectin pathways, although not explored in this work, function in 
synergy with the classical complement pathway to destroy pathogens and ensure homeostasis. 
The alternative pathway serves as sentinel to monitor pathogen entry, as it is constitutively 
active, with baseline activity via the spontaneous hydrolysis of the thioester of C3 [17, 18]. This 
bioactive C3 can then be modified to form the alternative C3 convertase, as described above. The 
lectin pathway is analogous to the classical pathway, in that mannose-binding lectin (MBL) or 
ficolins recognize and bind to sugar groups of a particular orientation on pathogen surfaces, 
namely glucose and mannose. Once activated by mannose-associated serine proteases, this 
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complex cleaves C4 and C2, as does the C1 proenzyme complex. The classical pathway C3 
convertase is then formed.  With regard to bacterial pathogens, the lectin pathway is essential in 
countering clinically-relevant Gram-positive bacteria, including Streptococcus pneumoniae [34] 
and Staphylococcus aureus [35] though also involved in the response to Gram-negative 
Pseudomonas aeruginosa [35].         
1.3 Particle Platforms for Complement Activation 
 By convention, microparticle and nanoparticle formulations intended for therapeutic or 
diagnostic use are designed to limit opsonization by serum proteins and complement, as this 
reduces phagocyte uptake and subsequent immune responses. Perhaps the most extensively 
utilized approach is to engineer the surface chemistry, usually by integrating poly(ethylene 
glycol) (PEG) or particular zwitterionic polymers to form a hydration shell around the particle 
and thereby sterically hinder protein adsorption [36, 37].  However, as the role of complement in 
adaptive immunity has been clarified, there has been increasing interest in using particle 
platforms to induce complement activation and modulate sought elements of this response. The 
complement protein C3 and its split products C3b and iC3b (inactivated C3b opsonin) are 
intriguing effectors to target, as C3 and antigen-bound C3b has been demonstrated to boost 
inflammatory T cell activity [20, 38], whereas iC3b binding to dendritic cells may promote 
tolerance [39, 40]. This induction of tolerance likely contributes to tumor evasion of immune 
surveillance.  
 Complement-stimulating capability in the context of tuning adaptive immunity has been 
most extensively studied regarding material surface chemistry. These particles are intended 
almost exclusively as vaccines. Reddy and colleagues introduced complement-activating 
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poly(propylene sulfide) nanoparticles that preferentially accumulated in the lymph nodes and 
prompted specific, complement-dependent immunity in vivo [41].  Given the high density of 
hydroxyl groups on the particle surface due to Pluronic stabilization, it was purported that they 
readily bound C3b and initiated activation via the alternative pathway. Thomas et al. improved 
upon this further, providing better control of C3b deposition on the particles by increasing the 
negative surface charge and nucleophile abundance with the addition or substitution of/with 
carboxyl-terminated Pluronic [42]. Others have utilized complement-modulating microparticles 
in tandem with vaccines, and found that those cross-linked with C3b-binding moieties provide 
higher antigen-specific antibody titers and increased inflammatory cytokine production upon 
restimulation ex vivo [43]. In addition to materials chemistry, it appears that complement-
modulating particle morphologies that delay lymphatic drainage, extending the duration of 
complement signaling in antigen presentation, best augment immune responses [44].  
 Although there is extensive understanding of the influence of Fc valency and orientation 
in the regulation of complement activation in vitro and its influence in the downstream immune 
response [45-47], there is little work comparatively with Fc-coated platforms. Of this, much of 
the work related to Fc-coated microparticles in immunomodulation concerns how they may be 
employed to spur macrophage phagocytosis and cytokine release [48-51]. As we have previously 
demonstrated, Fc-coated microparticles can be designed to substantially modulate the 
complement cascade by tuning Fc valency and sterics as a result of Fc abundance on the particle 
surface [50, 52]. Interestingly, we have shown that by coating microparticles with the antigen 
recognized by the initiating IgG such that the IgG binds in a uniform orientation, there is a 
immunosuppressive response in vitro [33]. But when the antigen coating is absent and the IgG 
binds randomly, robust complement activation is better localized into the surrounding milieu, 
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increasing cytotoxicity. This non-oriented Fc configuration also allows for a greater effective 
cytotoxic radius compared to the oriented Fc microparticles. For this reason, all particle types in 
this study utilized non-oriented anti-BSA IgG to initiate the complement system. 
                     
1.4 Bacterial Strains and Gram Classification 
 
1.4.1 Gram Classification and Complement Recognition 
 
 By convention, bacteria are classified according to cell wall composition, as evidenced by 
Gram staining (Figure 1.3 A). Almost all possess a peptidoglycan layer comprised of alternating 
N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid polysaccharide chains (MurNAc) 
[28]. Gram-negative bacteria display an inner and outer phospholipid membrane separated by a 
thin peptidoglycan layer (1-7 nm) [28]. The outer membrane is of particular significance as it 
contains the glycolipid lipopolysaccharide (LPS). Gram-positive bacteria have a single 
phospholipid membrane coated by relatively thick peptidoglycan (20-80 nm). Gram-positive 
peptidoglycan is often attached to teichoic acids (wall teichoic acids, WTAs) and the 
peptidoglycan may be bound to the underlying membrane via lipoteichoic acids (LTAs). 
Although peptidoglycan potently triggers complement activation [53], it is usually buried 
beneath polysaccharide chains (Gram-positive) or the outer membrane (Gram-negative), so 
complement initiators must recognize outfacing moieties. A thorough summation of targets and 
recognition molecules for both Gram classification is depicted in Figure 1.3 B. MBL binds LPS 
displayed by Gram-negative bacteria [54] as well as Gram-positive WTA [55]. Ficolins are 
distinguished by their ability to recognize acetyl groups, such as those of GlcNAc, as well as an 
array of sugars [28]. This recognition of GlcNAc may allow for peptidoglycan binding on Gram-
positive bacteria. C1q may bind via the traditional IgG cluster/single IgM, or via pentraxins such 
as SAP and CRP. Notably, SAP can bind carbohydrate moieties in both Gram-positive 
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(peptidoglycan) and Gram-negative bacteria (LPS) [56]. C1q may also bind independently to 
several outer membrane constituents in Gram-negative bacteria [28, 57] as well as lipid A of LPS 
[29]. The alternative pathway has historically been viewed as a means of amplification rather 
than a means of detection, but there is evidence that properdin (or Factor P), a plasma protein 
that aids in the formation of the alternative pathway C3 convertase, binds the LPS of particular 
Gram-negative strains, initiating the cascade [58]. Of relevance to our application, the classical 
pathway in Gram-negative E. coli strains is investigated (C1q-mediated), and although we did 
not determine the influence of the lectin and alternative pathways, they are most likely involved.           
 
Figure 1.3: (A) Cell wall structure and composition of Gram-negative and Gram-positive bacteria. Figure adapted 
from [59] (B) Recognition molecules of the central compement system pathways and their association with Gram-
negative and Gram-positive strains. These include those of the alternative pathway (properdin), lectin (MBL, 
ficolins collectin-11), and the classical pathways (C1q). Key: LPS, lipopolysaccharide; PS, polysaccharides; WTA, 
wall teichoic acid;  GlcNAc, N-acetyl glucosamine; LTA, lipoteichoic acid; MBL, mannose-binding lectin; SAP, 
serum amyloid P; CRP, C-reactive protein; IgG, immunoglobulin G. Figure from [28].  
 
1.4.2 Escherichia coli 
 
 E. coli is a facultatively anaerobic, Gram-negative bacterium naturally-occurring in the 
intestinal flora of humans and other warm-blooded animals. Given the ease and minimal expense 
with which it is cultured in the laboratory, it is of longstanding use as a model organism in 
microbiology. The species is massively diverse; only 20% of sequences in a typical E. coli 
A B 
 9
genome are conserved amongst all unique subgroups [60], termed strains. Strains can be further 
differentiated irrespective of evolutionary lineage by the expression of particular surface 
antigens, known collectively as the serotype. The main E. coli antigens are the O-antigen, a 
component of the outer lipopolysaccharide layer, the K-antigen, found in the capsule, and the H-
antigen, located in the flagellin [61] (Figure 1.4 A).  Due in part to recognition of these antigens 
by the humoral immune response of the host, E. coli are susceptible to complement mainly via 
the alternative and classical pathways [62]. 
               
 
Figure 1.4: (A) E. coli serotype antigens used in strain classification. Figure adapted from (Université de Montreal 
EcL) (B) Representative Gram-negative cell wall structure, indicating the positions of lipid A and the O-antigen 
within the outer membrane. Figure adapted from [63].  
                           
 As E. coli continuously evolve through gene duplication, mutation, conjugation 
(horizontal gene transfer), and bacteriophage-mediated transduction, pathogenic strains have 
diverged. Most notable of these is E. coli O157:H7, which is included in this study. E. coli O157 
is frequently the causative agent in outbreaks of foodborne illness, and infection may be 
characterized by severe abdominal pain that in some patients can progress to hemorrhagic 
diarrhea, with mild or no fever [64]. Infrequently (5-10% of cases), infection may progress to 
hemolytic uremic syndrome (HUS) [65, 66], which can result in potentially life-threatening 
kidney injury. The majority of HUS cases in the United States are due to E. coli O157, and 
young children, the elderly, and the immunocompromised are most at risk. Critical to its 
pathogenicity are numerous virulence factors, namely the secretion of hemolysin and Shiga 
toxins 1 and/or 2 [65]. Shiga toxins released in the gut bind to and induce cell death in 
commensal bacteria, susceptible cells of the endothelium upon translocation across the intestinal 
BA
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epithelium, and in renal tubular and glomerular epithelial cells [67, 68]. Upon cell entry, the 
toxin inhibits tRNA binding to ribosomes, occluding protein synthesis [69]. Shiga toxin is 
encoded by a prophage integrated in the E. coli O157:H7 genome, which may be triggered by 
antibiotic use [70]. For this reason, treatment with antibiotics is contraindicated [71]. As 
extensive complement activation is associated with both E. coli O157 infection and Shiga toxin 
bioactivity in the progression to HUS [72-74], the best-suited therapeutics will likely aim to 
impair rather than encourage complement formation [75]. Interestingly, E. coli O157 produces 
several virulence factors in addition to Shiga toxins that allow for complement evasion. The 
serine protease EspP cleaves C3/C3b and C5 [76] and the metalloprotease StcE cleaves C1-
esterase inhibitor, increasing its capacity to neutralize C1s (preventing classical pathway 
initiation) and the mannose-associated serine proteases of the lectin pathway [74]. In addition, 
StcE can bind to both O157 and host surfaces, tethering C1-esterase inhibitor to shield the 
pathogen. For these reasons, although a complement-based therapeutic might be unsuitable for 
O157, demonstrating selectivity with the targeted microparticles might more effectively bypass 
complement subversion, and provide insight for future therapeutic strategies. 
 E. coli J5 is termed a rough mutant of serotype O111:B4 as the O-antigen component of 
its lipopolysaccharide is absent, thereby exposing the more evolutionarily conserved core and 
lipid A of the lipopolysaccharide [77] (Figure 1.3 B). As such, this strain was of considerable 
clinical interest for vaccination to prevent bacteremia and sepsis caused by a host of Gram-
negative bacteria [78-80]without the need for antibiotics, which may incite endotoxin release. In 
this study, J5 was selected as a model bacterium given its complement sensitivity and the array 




 Antibiotics of longstanding clinical use are nonspecific, resulting in toxicity to 
commensal bacteria that are central in preventing colonization of mucosal surfaces by pathogenic 
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bacteria, establishing mucosal immunity, and maintaining tolerance to food antigens in the gut, 
among other functions [11]. Not only do these antibiotics apply selection pressure to favor more 
entrenched antibiotic resistance, but there is evidence to suggest that their interference with 
commensals may contribute to numerous pathologies.     
 We have previously demonstrated that the extent and orientation of IgG surface coverage 
modulates the complement response and affects the availability of its soluble mediators, with 
non-oriented, high-density IgG most favorable to cytotoxicity. In combining targeting and 
complement activation into a single particle, we aim to improve cytotoxicity against a sought 
strain, presumably by improved localization of the corresponding particle. The particles and their 
nomenclature are shown in Figure 1.5 below. No strain-specific antibiotic modality currently 
exists for Gram-negative bacteria (antibiotics specific to Staphylococci are in clinical trials 
[Debiopharm Group]. Although the base particles are too large (1 µm) to be therapeutically 
practical and are not biodegradable, this study is intended as a proof-of-concept measure to 
demonstrate that the nonspecific complement system may be targetable.   
 
 






 This research aims to demonstrate a more targetable platform to localize complement-
mediated cytotoxicity to a sought bacterial strain. If successful, we will have developed a 
targeted, modular, “customizable” antibiotic that provides a tunable response with the adjustment 
of the initiating Fc orientation and abundance. In addition, the cytotoxic and inflammatory 
responses are better restricted given the targeting capacity and an inherent immune response is 
harnessed and can be abated by the human body’s own homeostatic control.   
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CHAPTER 2: METHODS 
2.1 Functionalization of Non-Targeted (UT and MUT) Particles 
 Carboxylated polystyrene microparticles 1 µm in diameter (Bangs Laboratories, Fishers, 
IN) were centrifuged and washed several times in PBS (5500xg, 5 min each) to remove buffers 
and preservatives such as sodium azide from the manufacturer’s formulation. These polystyrene 
microparticles were selected as the base material as they are highly uniform, their IgG 
conjugation and saturation schemes are standardized as previously determined by the 
manufacturer (Bangs Labs Technotes 204 and 206), and we have previously utilized them for 
complement modulation [33, 50, 52]. Our previous work has investigated the impact of both 
particle Fc density [33, 52] and orientation [33] in augmenting or diminishing the localized 
classical complement response, and we have determined that cytotoxicity is most strongly 
associated with high Fc density and randomized display. To form the untargeted particles (UT), 2 
mg/mL polyclonal rabbit anti-BSA (ThermoFisher, Waltham, MA) was added in sufficient 
volume to provide 2x particle surface saturation and allowed to adsorb nonspecifically, as 
previously reported [33]. The mixed untargeted particles (MUT) were synthesized similarly, with 
the addition of a mouse monoclonal antibody specific to one of the test strains (either anti-E. coli 
O157 IgG or anti-E. coli J5 IgG from Abcam, Cambridge, MA) at half the amount recommended 
by the manufacturer for various extents of particle saturation (2x, 1x, and 	x) for a single IgG 
(Bangs Labs Technote 205). For example, 2x anti-O157 MUT received IgG volumes suggested 
for the 1x saturation extent of each antibody (6.3 µL anti-O157 and 7.6 µL anti-BSA).  
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Figure 2.1:  Flow diagram of UT and MUT particle functionalization. For convienience, the multiple wash steps 
between the addition of each component were omitted.  
 
2.2 Biofunctionalization of Mixed Targeted (MT) Particles 
 To determine any benefit of targeting without hemispherical segregation of binding, 
mixed targeted particles (MT) were developed, which differ from the UT and MUT in that the 
binding antibody is conjugated such that the antigen-binding fragment (Fab) projects outward. 
This was accomplished via the streptavidin-biotin interaction, in which the streptavidin-
conjugated targeting antibody is mated to the biotin-terminated crosslinker NH2-PEG-biotin. But 
first the carboxyl surface must be activated such that the crosslinker binds in the proper 
orientation.  
 EDC is a water-soluble carbodiimide crosslinker that primes exposed carboxyl groups, 
creating an amine-reactive ester intermediate for covalent linkage to a protein containing a 
primary amine group [81]. For optimal stability, EDC must be used within an environmental pH 
between 4.0-6.0 [81]. Also, EDC is highly hygroscopic, so solutions must be freshly prepared 
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and utilized immediately. Here, 25 µL of 0.2 mg/mL EDC (ThermoFisher Scientific, Waltham, 
MA) in pH 6.0 coupling buffer (Polysciences, Warrington, PA) was added to each particle pellet 
of approximately 3.6*108 particles, which were then incubated at room temperature for 15 
minutes prior to protein conjugation. Immediately afterwards, the tubes were centrifuged and the 
supernatant was aspirated for the addition of NH2-PEG-biotin.  
 EZ-Link NH2-PEG11-biotin (ThermoFisher Scientific, Waltham, MA) was selected given 
the long PEG spacer arm, which would minimize steric hindrance amongst both the binding and 
activating moieties. The concentration required for half saturation of particles was determined 
via titration and labeling with allophycocyanin (APC)-labeled streptavidin. Briefly, 39 mg EZ-
Link NH2-PEG11-biotin was dissolved in 1 mL coupling buffer (50mM) and diluted serially to 
62.5 µM. From these solutions, 100 µL in coupling buffer was added to EDC-activated particle 
pellets as described above. The tubes were then incubated for 2 hr with end-over-end mixing. 
Next, 5 µL of the particle solution was incubated with 3 µL 0.2 mg/mL APC-streptavidin in PBS 
for 1.5 hr and then diluted 1:100. Flow cytometry was conducted (BD Accuri C6, BD 
Biosciences, San Jose, CA) with median fluorescence intensity (MFI) determined via FlowJo 
v10.0 software (FloJo LLC, Ashland, OR). Amine-PEG-biotin saturation was determined as the 
point of maximum MFI, or 5 mM. For particle functionalization, 2.5 mM of NH2-PEG-biotin 
was added to EDC-activated particle pellets as previously described. Various amounts of 
streptavidin-conjugated antibody to a particular bacterial strain and anti-BSA were then added at 




2.2.1 Antibody Conjugation to Mixed Targeted Particles 
 To affix the targeting antibodies to the biotinylated gold hemisphere, mouse monoclonal 
antibodies anti-E. coli O157 IgG and anti-E. coli J5 IgG (both from Abcam, Cambridge, MA) 
were conjugated with streptavidin using Lightning-Link® Streptavidin Kits (Innova Biosciences, 
Cambridge, UK) according to the manufacturer’s instructions. They report that the kit has been 
designed such that each antibody can bind a maximum of three streptavidin molecules. Not only 
does this multivalent display improve the likelihood of biotin binding, but as the kit functions by 
activating amines, this reduces concerns of surplus streptavidin conjugation, which might 
otherwise prevent an upright IgG orientation. Anti-E. coli J5 was first concentrated to 1mg/mL 
for use with the streptavidinylation kit via 3 kDa or 10 kDa MWCO spin filters (EMD Millipore, 
Billerica, MA). This filtration technique also allows for the removal of the antimicrobial sodium 
azide contained in the formulation, which would otherwise impede conjugation to amines and 
confound cytotoxicity results. 
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Figure 2.2:  Flow diagram of MT particle functionalization. For convienience, the multiple wash steps between the 
addition of each component were omitted.  
 
2.3 Particle Labeling for Counts and Labeling Determination 
  
 To verify IgG adsorption or conjugation to each particle type, 5 µL of particle solution 
was stained with Dnk anti-Rb Dylight 650 (Abcam, Cambridge, MA, bound anti-BSA) and Dnk 
anti-Ms Alexa Fluor 488 or Gt anti-Ms FITC (both ThermoFisher, Waltham, MA, bound Ms 
targeting antibodies), with the exception of the UT particles, which were stained with the anti-Rb 
secondary alone. The amount of secondary antibody was adjusted according to the primary IgG 
saturation extent and primary IgG concentration used to form the particles, as previously 
determined [52]. Secondary antibodies were reacted with the particles in 50 uL total volume with 
end-over-end mixing in the dark for 1 hr. The particles were then centrifuged (5500xg, 8 min), 
aspirated, and resuspended to 500 uL in PBS (1:100 dilution) for analysis via flow cytometry.          
2.4 Flow Cytometry for Particle Counts and Labeling Verification 
 To determine particle counts for binding and cytotoxicity experiments as well as to verify 
protein conjugation, the Accuri C6 flow cytometer (BD Biosciences, San Jose, CA) and its 
integrated analysis software were utilized. Bare polystyrene particles were used to identify the 
particle population gated on FSC vs SSC, for a total of 300,000 events. The intensity distribution 
for 100,000 events was determined for each particle type and extent of IgG coverage in the FL1 
(Alexa Fluor 488) and FL4 (Dylight 650) channels. Labeled particles were those with more 
pronounced fluorescence intensity in FL4A or both FL4A and FL1A with respect to the 
unfunctionalized control, as appropriate. To determine counts, the overlap of the particle gate 
and the population with the sought fluorescence configuration was determined, and the count 
was considered the quotient of this population and the volume of sample analyzed. All analyses, 
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median fluorescence determination, and plotting was completed in FlowJo v10 software 
(Ashland, OR).  
 
2.5 Bacterial Strains 
 
 E. coli serotypes O157:H7 (strain CDC EDL 933, ATCC® 43895™) and J5 (mutant of 
serotype O111:B4, strain ATCC® 43745™) were purchased from the American Type Culture 
Collection (Manassas, VA). All strains were used as received, cultured in Luria-Bertani (LB) 
broth and plated on LB agar (both Fisher Scientific, Waltham, MA).    
  
2.6 Serum Collection and Heat Inactivation 
 
 Blood was donated by a single healthy volunteer to minimize batch variability. Blood 
was first allowed to clot at room temperature for 45 min. To isolate serum, the blood was 
centrifuged at 1000 xg at 4°C for 15 min. Residual platelets were removed by pelleting upon 
centrifugation at 900 xg for 5 min, with the serum decanted as the supernatant. The serum was 
then divided to aliquots stored at -80° C. Serum was thawed immediately before use.  
 To produce heat-inactivated serum, 200 µL of normal human serum was incubated for 2 
hr at room temperature with approximately 9●106 4 µm Protein G – labeled particles developed 
in our lab. The particles were then removed by pelleting at 6100xg for 5 min. Next, the aliquots 
were incubated in a water bath set at 56°C for 30 min to denature complement proteins. The 
tubes were then left to cool to room temperature before overnight storage at 4°C. To remove any 
residual IgG precipitate formed during heat inactivation, the serum was centrifuged at 800xg for 
30 min and the supernatant recovered. This fully-processed heat-inactivated serum was stored in 
aliquots at -80°C until use.      
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2.7 Cytotoxicity Analyses  
 
 Cytotoxicity was determined via manual colony counting of serially diluted mixtures of 
bacteria in LB broth, particles, and serum. Approximately 500,000 bacteria (as determined by 
absorbance, OD600) suspended in 10 µL of LB broth were combined with various numbers of 
particles in 30 µL PBS, according to the sought particle-to-bacteria ratio. LB Broth was then 
added, followed by serum to initiate the complement cascade. Serum was diluted in broth such 
that it comprised roughly 10% or 1% of the total mixture volume of 125 µL – 0.2 (J5) - 1% 
(O157) serum allowed for discernment of differences among particle conditions after plating, as 
more concentrated serum could completely preclude colony growth. To verify that any cytotoxic 
effect was complement-mediated, functionalized 2:1 anti-J5 microparticles and bacteria were 
incubated with serum depleted of IgG and heat-inactivated, and a non-functionalized particle and 
untreated bacteria condition was included.  
 Upon serum addition, sample tubes were incubated for 3 hr at 37°C, followed by tenfold 
dilution in LB broth 5-6 times such that colony numbers suitable for manual counting could be 
generated. A 10 µL aliquot of the mixture was added to 100 µL broth, mixed and this process 
was repeated sequentially. The fifth and sixth dilutions were kept for plating; four 10 µL droplets 
were placed on LB agar plates. The plates were then incubated at 37°C for 16 hr, photographed 
and colony forming units counted. Bacterial lawns were given a value of 160 colonies, and 
incomplete lawns 120. Cytotoxicity was determined as the difference between the average 
colony count per condition compared to the bacteria in broth control. Statistics were determined 




Figure 2.3:  Schematic overview of plating cytotoxicity experiments. 
 
2.8 Confocal Microscopy Analysis of Particle Targeting 
 Confocal microscopy (Zeiss Elyra PS.1/LSM 780, Zeiss, Oberkochen, Germany) was 
implemented to verify binding between particles and their target strains. Glass microscope slides 
were first sonicated in ethanol for 30 min, followed by washing in DI water. To adhere bacteria 
to the surface, 5 µL of 1.66 mg/mL Cell-Tak in 5% acetic acid (Corning Life Sciences, 
Tewksbury, MA), a formulation of mussel adhesion proteins, was mixed into a 60 µL droplet of 
PBS and incubated in the dark for 25 min. Approximately 5●106 bacteria (as determined by 
absorbance, OD600) were stained in 100 µL PBS via the LIVE/DEAD BacLight Bacterial 
Viability Kit (ThermoFisher Scientific, Waltham, MA) at 3 µL per sample. To remove excess 
dye, the bacteria were washed twice in PBS (6000xg, 10 min each). Next, 50 µL of the bacterial 
solution was added to the Cell-Tak region and allowed to attach in the dark for 25 min. 
Unattached bacteria were removed by aspiration. Particles (5●106) were incubated with Dnk 
anti-Rb Dylight 650 with end-over-end mixing for 1 hr and then washed once in PBS (5500x g, 8 
min) and resuspended to 25 µL in PBS. In this way, the particles could be identified by tagging 
the bound anti-BSA with lessened impediment to binding the bacteria. Particles were then added 
to the region and allowed to bind for 25 min. Unattached particles were then aspirated. A droplet 
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of mounting media (SlowFade Diamond, ThermoFisher, Waltham, MA) was placed over the 
region, a coverslip was applied, and the edges sealed with nail polish. The slides were cured at 
room temperature for 20 min before placing in an opaque box at 4°C overnight. Slides were 
imaged the following day.   
 Differences in binding proclivities amongst the particle types were compared by 
manually counting and determining the ratio of binding events to the number of total particles in 
10 separate frames acquired at the same zoom (0.7) set in the Zen 2012 software. To reduce 
crosstalk across fluorescence channels, spectral imaging (Lambda mode) was employed.       
2.9 iC3b and TCC ELISAs 
 To assess the effect of particle IgG display in variations in complement progression, 
complement mediators were quantified at the molecular level. Activation products iC3b and 
TCC upon serum exposure both in supernatant and adsorbed to the particles were determined by 
ELISA as described in [33]. Briefly, approximately 2●107 particles in 86 µL PBS was added to 
14 µL pooled normal human serum (Pierce, ThermoFisher Scientific, Waltham, MA) and 
incubated for 1 hr at 37°C to ensure robust complement activation. To isolate complement 
fractions in the supernatant from those absorbed to the particles, the particle solution was then 
centrifuged at 6000xg for 8 min and the supernatant separated. Both the particle pellet and 
supernatant were each diluted 1:200 and divided to the wells of a microassay plate included as 
part of the MicroVue iC3b or CH50 Eq ELISA kits (both Quidel, San Diego, CA). The CH50 Eq 
ELISA kit provides a proxy measure of total TCC as CH50 equivalent units per microliter. The 
CH50 unit corresponds to the test serum volume needed to lyse 50% sheep erythrocytes 
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sensitized to rabbit IgM, and is a standard method by which complement activation is 
determined.             
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CHAPTER 3: RESULTS 
 
3.1 Verification of Different Particle Classes with Flow Cytometry 
 
  
Flow cytometry was conducted to verify particle labeling and increasing surface coverage 
with larger amounts of IgG. After isolation of the particles by forward scatter – side scatter, this 
population was analyzed for fluorescence in the channels corresponding to Gt anti-Ms FITC or 
Dnk anti-Rb Alexa Fluor 488 (FL1) and anti-Rb DyLight 650 (FL4). Fluorescent signal above 
the background on a logarithmic scale (as determined from unfunctionalized particles) was 
considered to indicate labeling, with an increase in median fluorescence intensity in each channel 
suggesting greater IgG labeling extent. Median fluorescence intensity was selected as the 
labeling metric as it less sensitive than the mean to the skewness of flow cytometry data. 
Particles counts used in subsequent analyses (plating cytotoxicity experiments, confocal, etc.) 
were determined from dual-labeled particle concentrations. As we have previously characterized 
the labeling of the UT and the staining procedure was unchanged, the UT labeling results are not 
shown.         








Figure 3.1. (A) Histogram overlays of O157 median fluorescence intensity with increasing IgG surface coverage 
and (B) dual-signal fluorescence intensities and subpopulation proportions of J5 MUT particle variants.  
 
 
3.2.1 Targeted IgG Particle (MT) Labeling 
 
 
From the representative labeling experiments below, median fluorescence increases with 
theoretical IgG surface coverage for both the J5 and O157 MT. Both partition more fully to the 
dual-labeled type (upper right quadrant) with increasing IgG surface coverage, yet the dual-
labeled subpopulation is minimal for the  x J5, though it increases substantially thereafter. The 
remaining x J5 MT subpopulations (unlabeled, and singly-labeled with anti-BSA or anti-J5) 
contain roughly equal proportions of the particles. Perhaps the difference in the extent of anti-J5 




markedly affected by the charge of the protein and the surface charge density of the substrate 
[82]. The carboxylated polystyrene particles are negatively charged [83], but their surface change 
density is altered by ongoing anti-BSA adsorption and the attachment of the streptavidinylated 
antibacterial IgG to the crosslinker. The O157 IgG may be more robust to this process, and the 
relation of IgG charge and surface density pre- and post-crosslinker addition warrants further 
investigation. 
    The x O157 MT display a more pronounced partition into the anti-BSA labeled 
subpopulation (lower right quadrant) at the lowest IgG concentration, but there is then a 
substantial shift to the dual-labeled subpopulation with increasing IgG. This increase in 
secondary antibody signal for the O157 MT is expected with an increase in available epitopes, 
suggesting increased labeling at higher primary IgG concentrations in combination with the 











Figure 3.2. (A) Histogram overlays of median fluorescence intensity with increasing IgG surface coverage and (B) 
dual-signal fluorescence intensities and subpopulation proportions of J5 MT particle variants. Note that the J5 and 












Figure 3.3. (A) Histogram overlays of median fluorescence intensity with increasing IgG surface coverage and (B) 
dual-signal fluorescence intensities and subpopulation proportions of O157 MT particle variants. Note that the J5 
and O157 MT particles were run in the same experiment, so the unfunctionalized control is shared.      
   
3.2 Plating Cytotoxicity Experiments 
 
           To distinguish the cytotoxic effectiveness of the particle types and any influence of 
surface coverage, in vitro plating experiments were conducted, as detailed in Section 2.7. 
Briefly, particles were incubated 5:1 with bacteria (2,500,000 particles and 500,000 bacteria), 
broth, and normal or heat inactivated human serum. Tubes were incubated at 37°C for 3 hr 
followed by serial dilution and further incubation of 105- and 106-fold dilution agar plates as 




but similar experiments with decreasing serum concentration from 5% by volume to the point at 
which sensitivity was evident but colony formation was still substantial.  
 
3.2.1 Randomized IgG Particle (UT and MUT) Cytotoxicity 
 
 
          UT and MUT particles of increasing Fc surface coverage were evaluated to determine 
whether including a targeting monoclonal IgG, even if randomly adsorbed to the particles, 
provided any cytotoxic benefit. Only the 2x Fc saturation UT particles were evaluated as we 
have previously demonstrated increasing cytotoxicity with Fc saturation, with maximal effect at 
2x saturation for the same anti-BSA IgG and base particles (also called 2:1 non-oriented) [33].  
              From Figure 3.4, for the 106-fold dilution there is some increase in antibacterial 
capacity against the complement-sensitive J5 with increasing Fc coverage for the MUT, but 
cytotoxicity is most dramatic for the 2x UT and this is only group with statistical significance (p 
= .0077) relative to untreated cells. This may be due to maximization of available Fc for 
complement activation – a fraction of the targeting IgG Fc is unable to bind C1q due to sterics 
upon binding bacteria. Additionally, the subclass composition of each IgG is important, as they 
vary in the extent of classical complement fixation [84]. The polyclonal anti-BSA consists of an 
array of subclasses whereas the monoclonal targeting IgG are all the same subclass; complement 
activation may be greater if certain subclasses dominate among the mixture. Given that heat 
inactivation of the serum combined with the 2x MUT displays minimal effect and is most like 
the untreated cells, complement-mediation of the effect is implied, although for such dilute 
serum toxicity is already limited. The unfunctionalized particles activate complement 
themselves, likely as C3 and C4 bind carboxylated polystyrene possibly due to electrostatic 
interactions [85]. Complement activation then proceeds through the alternative pathway.            
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         By contrast, MUT is more suitable for the complement-resistant O157 strain, and although 
the antibacterial effectiveness is greatest for the 2x surface coverage (p = .0053 relative to 
untreated cells), whether the factors are correlated is unclear. With targeting, complement may 
be better localized. Surprisingly, O157 viability increases for the 1% serum only condition. 
However the capability of E. coli to persist in serum via nucleotide synthesis has been described 
[86], and this may occur despite complement in dilute serum. To our knowledge this has not 
been previously reported in O157, and instead may be due to the inherent variability in plating 
assays [87, 88]. As the heat inactivated serum was shown not to be significantly toxic in 
combination with 2x MUT against J5, it was not evaluated with O157.       











Figure 3.4. The viability of J5 (A) and O157 (B) E. coli following treatment with single-source normal human 
serum and particles of randomized Fc with varying levels of surface coverage. Particles were added at a 5:1 ratio to 
bacteria (2,500,000 particles to 500,000 bacteria). Results depict averages from three experiments. Error bars 




 As a means to reduce this variability, colony counts for the 105 dilution were also 
recorded, as it is recommended that plates counts consist of at least 25 colonies per replicate, as 
there may be dubious accuracy below this threshold [89]. This occurs because CFU are 
contended to follow a Poisson distribution, so error is the square root of the average (USP 
<1227>). With plate counts less than 25, error as a percentage of the mean increases 
considerably [89]. From Figure 3.5 below in which the plate counts from the 105 and 106 
dilutions are compared, the most cytotoxic of the particle variants remains the same, but the 
change in the supposed effect of Fc coverage differs according to target strain. Although the 2x 
UT is again most effective against J5, cytotoxicity decreases with increasing Fc saturation, 
whereas the opposite appears in the 106 dilution, at least prior to 2x surface saturation. Regarding 
O157, 2x MUT still predominates, with cytotoxicity greatest for very low or very high Fc 
saturation, but the differences amongst the MUT are much less pronounced. Given these 
observations, additional trials should be conducted and an error cutoff established (ex. 20% from 
the mean of triplicate experiments, as suggested in a seminal paper by Breed and Doeterrer [88]). 
Note that the 106 dilution plots are extrapolated from the previous figure.  











Figure 3.5. Comparison of strain viability of E. coli J5 (top) and O157 (bottom) by dilution after incubation with 
serum and MUT or UT particles of varying targeted and complement-activating IgG coverage, as applicable. All 
plating experiments utilized a 5:1 particle-to-bacteria ratio (2,500,000 particles to 500,000 bacteria). Note that the 
105 dilution of the O157 particles summarizes average results from two experiments, while all others consist of 
three. Error bars represent the standard error of the mean. **** p <.001, ** p < .01, * p < .05, relative to untreated 
cells. 
 
3.2.2 Targeted IgG Particle (MT) Cytotoxicity 
 We hypothesized that cytotoxicity would be improved with targeting, particularly with 
targeting IgG oriented such that the Fab regions project outward without steric hindrance from 
the complement-stimulating IgG. The MT particles differ from the MUT panel in that a 
crosslinker (NH2-PEG-biotin) in theory occupies half of the available surface area per particle, 
with the remainder occupied by the nonspecific polyclonal activating IgG (anti-BSA). The 
targeting IgG is then bound to the crosslinker via the highly selective biotin-streptavidin 
















































3.6, the MT elicit little effect against either J5 or O157, even at a 5:1 particle-to-bacteria ratio. 
As the PEG chains of the crosslinker are not rigid, perhaps their movement blocks the binding of 
the IgG. For reasons discussed in the previous subsection, only the 105 dilution was evaluated. 
Particles seem to be slightly cytoprotective for J5, but any correlation with IgG density is 
uncertain. There is minimal improvement in O157 with increasing Fc coverage, but the variation 
is within the bounds of the error. The outcome of HI serum treatment for the J5 suggests that it 
may still activate complement substantially -  perhaps there is residual heat-aggregated IgG that 
was not removed with the protein G microparticles. Yet O157 viability increases sharply with 
heat-inactivated serum relative to cells in broth alone, and this may be due to greater availability 















Figure 3.6. Colony counts of E. coli J5 and O157 treated with specified serum concentrations and MT particles of 
varying targeted and complement-activating IgG coverage. Particles were added at a 5:1 ratio to bacteria (2,500,000 
particles to 500,000 bacteria). Results depict averages from three experiments. Error bars represent the standard 




3.3 Confocal Binding Assay 
 
Given the counterintuitive cytotoxicity results, targeting proclivity differences between 
the UT, MUT, and MT were evaluated with a confocal binding assay, as described previously.     
Internally-labeled E. coli of the target strain was adhered to glass slides and then incubated with 
fluorescently-labeled 2x saturated particles of each configuration against the corresponding 
target strain. To distinguish particles, anti-Rb DyLight 650 specific for the anti-BSA was 
utilized. As variance in particle and bacterial abundance per imaging location was inevitable, 
binding capacity was determined to be the total number of binding events divided by the total 
number of particles per frame. A binding event was defined as overlap or the adjoining of 
particle and bacterium, and any particles in clusters were counted as individuals.                         
              
      
Figure 3.7. (A) Representative confocal imaging frame of 2x MUT J5 against J5 bacteria. The white arrows indicate 
putative binding events. (B) Comparison of binding proclivities for each 2x saturation anti-J5 particle type against J5 
across 10 imaging frames. The 10 imaging frames per particle type used for the analysis originate from the same 
slide. **** p < .0001 relative to 2x UT, #### p < .0001 relative to 2x MT J5.  
 
 The MUT drastically improves binding proclivity relative to the others, although it is 
variable. As expected, the UT did not bind apart from negligible off-target binding. Surprisingly, 
A B 
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the MT displayed minimal binding. Combined with the results of the plating experiments, this 
may imply that the physical properties of the crosslinker are unsuitable to allow for robust 
binding, or that the targeting IgG do not attach in the proper orientation, among other 
possibilities. To determine the theoretical half-saturation value of the crosslinker, it was apparent 
that the crosslinker bound (NH2-PEG-biotin), as substantial signal was detectable with a 
fluorescent streptavidin conjugate (data not shown). Further, the streptavidinylated targeting IgG 
bound, as verified by flow cytometry in Section 3.1. In addition to testing the anti-O157 particle 
variants, future work must include another means to confirm the presence of streptavidin 
attached to the particles, such as an in vitro assay involving crosslinker-only-conjugated MT 
particles binding to biotinylated serum albumin adsorbed to a solid surface.    
      
3.4 iC3b and TCC ELISAs 
 
  
As we had previously demonstrated that IgG orientation may affect the abundance of 
complement mediators both bound to particles and available to opsonize targets in the 
supernatant [33],  we evaluated the levels of iC3b and TCC for each O157 2x saturation particle 
variant post-activation. We were also interested in determining whether cytotoxicity correlated 
with the patterns of complement species released into the supernatant by each particle type. Both 
were run simultaneously using samples from the same reaction vials. Anti-O157 particles were 
intended as representative of dual-labeled particles. Given that the blank wells (no sample, but 
processed identically) displayed suspiciously high background, the iC3b ELISA results are 
inconclusive (data not shown). From the CH50 ELISA (proxy measurement of TCC, Figure 
3.8), there are noticeable differences in complement sequestration and dissemination amongst the 
particle types. The MUT sequester the most TCC, yet prompt little TCC formation in the 
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supernatant. The UT and MT bind TCC at about the same extent, but slightly more TCC was 
present in the supernatant for the MT particles. None of the differences were substantial enough 
to be statistically significant. 
 
Figure 3.8. CH50 (TCC) ELISA to quantify TCC both adsorbed to particles and free in the supernatant resulting 
from the activation of each O157 2x saturation particle variant. After 1hr incubation at 37°C in pooled NHS, the 
particles were isolated and diluted 1:200 in specimen diluent (reagent included with kit) for ELISA analysis. The 
results display mean and standard error determined from three replicates.     
 
There does not seem to be a clear relationship between TCC and cytotoxicity, as the MT 
were largely ineffective in plating experiments against either target strain. However, perhaps the 
MT overtake the MUT at higher doses - the particle counts used here are 8-fold that of the 
plating experiments. Yet there were some issues with the experimental execution itself. Heat 
aggregated gamma globulin (HAGG), a collection of heat-formed immune complexes, was 
included with the kits as a positive control, but it was not tested. Also, the slope of the 
concentration versus absorbance standard curve was slightly below the minimum recommended 
by the manufacturer (.0024 vs .0033), although the r2 value was sufficient (>.99).  































CHAPTER 4: DISCUSSION 
 
            Of the candidates, the MUT is clearly best suited to both bacterial targeting and 
cytotoxicity. The UT may be more cytotoxic to J5, but for any translational potential the activity 
of the MUT against the virulent O157 is more relevant. Surprisingly, orienting the targeting IgG 
does not seem to provide any benefit, although further examination of the crosslinker and its 
adsorption behavior should be undertaken to confirm this claim. Even more counterintuitive is 
that the MUT bind their target much more readily, but this must be verified for O157 strains, and 
to non-corresponding targets as well. The ELISA results seem to conflict with the cytotoxicity 
results – the 2x MUT O157, at least with anti-O157 IgG, sequesters the majority of TCC 
generated to the particle – but perhaps this view is incomplete, and it is the localization of 
complement from the binding of multiple particles that enhances cytotoxicity. The alternative 
pathway is unlikely to be augmented greatly by the orientation of IgG, but with certain molecular 
signatures (particularly hydroxyl and amine groups) more available on IgG, C3b deposition may 
be increased. In addition to the elements of the classical pathway, any changes in C3b, Factors B, 
H, and I should be analyzed. Assessment of the alternative pathway by preincubating serum with 
EGTA was not undertaken due to concerns about possible confounding effects of EGTA-induced 
E. coli morphology changes [90], but a different means of testing is recommended.     
 Pathogens generally avoid opsonization and destruction via complement by antigen 
modulation and blockade of complement mediator binding or by prompting their degradation 
once bound. For example, enzymes secreted by Pseudomonas aeruginosa degrade C1q as well as 
the various forms of the C3 opsonin [91]. Pathogenic E. coli may also vary their surface antigens 
in response to complement-induced stress – the uropathogenic strain CFT073 can downregulate 
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OmpC, a key surface antigen recognized by IgG in prompting the classical pathway [92]. 
Particular strains may possess multiple complement evasion mechanisms. Staphylococcus aureus 
displays streptococcal protein A, which inhibits classical pathway initiation by binding the 
antibody Fc region and inverting the molecule, thus avoiding C1q binding [93]. Another 
virulence factor S. aureus produces is staphylococcal complement inhibitor (SCIN), which binds 
and hinders the C3 convertase of any pathway, reducing C3b deposition [94]. Colonization may 
also be facilitated by the formation of biofilms, bacterial communities enmeshed in an external 
matrix mainly composed of polysaccharides. Typically a response to environmental stressors, 
biofilm incorporation provides protection from neutrophil phagocytosis, antibiotics, 
immunoglobulins, reactive oxygen species, and complement mediators as they are unable to 
penetrate deeply through the matrix [95]. Bacteria contained in the biofilm readily participate in 
horizontal gene transfer, and a subset can modulate genes that slow their metabolic efficiency – 
both of which features contribute to further antibiotic resistance [96]. With improvements to be 
discussed in future work, we anticipate that the MUT platform could be useful in clinical 
settings, despite its disappointing performance against the virulent O157. Given the 
considerations discussed above, a suitable bacterial target for the particle platform is preferably 
Gram-negative, must have a unique, accessible antigen, possess complement sensitivity, have no 
or limited proclivity to form biofilms, and be resistant to first-line antibiotics or display emerging 
resistance.  
 As virulent clinically-relevant bacteria innately resist complement-mediated destruction, 
the current MUT iteration at best may provide some benefit if used to supplement an antibiotic 
regimen as a sensitizing agent. Polymyxin B, a polycationic peptide antibiotic that selectively 
binds to Gram-negative bacteria (such as E. coli) via surface LPS, would be of particular interest 
 38
as it destabilizes the membrane, rendering the bacterium more sensitive to TCC [97]. Polymyxin 
B itself can prompt C3 and factor B secretion by monocytes [98] yet it may downregulate the 
neutrophil complement receptor CR3 [99]. A deacetylated form of polymyxin B, though weakly 
antibacterial if the activity is not totally abolished, has been noted to sensitize even serum-
resistant E. coli strains to complement and neutrophil activity [100]. Synergy with antibiotics has 
been reported for clinically-relevant bacteria including Klebsiella pneumonaie, Pseudomonas 
aeruginosa, and Salmonella typhimurium [101]. In addition, the toxicities of the parent 
compound are avoided [100]. Pairing the MUT particles with the deacetylated polymyxin B may 
be suitable to effectively target multidrug resistant strains that maintain sensitivity to colistins. 
MUT appears to sequester the most TCC of the particle variants, and should this hold true for 
others mediators, particularly C5a, the MUT may be best suited to septic situations, in which 
complement in serum is markedly elevated [102]. However, colistin is generally used as a last 
resort, and resistance has been increasing steadily in K. pneumonaie ([103, 104] and E. coli 
[105], as a transferable plasmid has been identified [106, 107]. Instead, innate antimicrobial 
peptides or synthetic mimics such as the ceragenins should be utilized.    
The only cathelicidin naturally-occurring in humans, LL-37, and its more potent synthetic 
analog, SAAP-148, have demonstrated efficacy against MRSA [108, 109] and multidrug 
resistant Acinetobacter baumanii both in vitro and in vivo [108]. Both organisms are listed by the 
CDC as impending ‘serious’ threats to public health [3]. LL-37 and SAAP-148, which are both 
cationic, interact with the phospholipids of both Gram-negative and Gram-positive bacterial 
membranes, causing them to destabilize [110]. Both have demonstrated the ability to impede 
biofilm formation and destroy established biofilms in antibiotic resistant bacteria [108, 111]. 
Although LL-37 prompts strong proinflammatory pathways [112], LL-37 and some derivatives 
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have demonstrated the ability to suppress the proinflammatory effects of LPS [113]. But this 
neutralization capacity and cytotoxicity can be reduced by serum [113]. To our knowledge, the 
immunological effects of SAAP-148 have not yet been reported. By pairing the MUT with LL-
37 or another modified cathelicidin, this reduction in serum cytotoxicity might be overcome, 
more of the cytotoxic effect may be directed to the target strain, and the agents that mediate 
serum suppression may be identified by binding the particles. The role of LL-37 in sepsis is 
highly complex, however, and its interaction with complement is still being elucidated.      
 MUT in combination with polymyxin B/nonapeptide might merit investigation for non-
bacterial drug resistant pathogens. Fungi of the Candida genus are opportunistic pathogens and 
are among the most frequent sources of nosocomial bloodstream infections [114]. The incidence 
of Candida infection is only increasing [115]. Mortality due to candidemia is significant, and 
patient stays in the intensive care unit are often extended several weeks relative to uninfected 
patients [116]. First-line treatment is often the antifungal agent fluconazole, but many common 
strains can be resistant –the most frequent C. albicans, as well as the more virulent C. glabrata 
and C. krusi, the latter of which can be innately resistant [117]. Clinical isolates of an emergent 
strain, C. auris, are almost exclusively fluconazole-resistant [117]. Fluconazole-resistant 
Candida are next treated with echinocandins, and C. glabrata in particular is increasingly 
resistant [118]. Patients with multidrug-resistant C. glabrata and C. auris often receive 
amphotericin B, which is infamous for its adverse side effects, namely a potent febrile reaction 
shortly after infusion, marked but reversible nephrotoxicity, hypokalemia, and anemia among 
others in already seriously ill patients [119].  
 Surprisingly, most of these disseminated Candida infections occur not in non-
immunocompromised or neutropenic patients, but those who have received gastric surgery, 
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broad-spectrum antibiotics, or catheterization for parenteral nutrition or venous injections [120]. 
In these instances, commensal populations and anatomical barriers that might provide immune 
protection are disrupted. Infection with C. albicans, the most extensively studied, stimulates all 
three complement pathways [121]. C. glabrata and C. krusei are known to prompt the alternative 
pathway, although there is also evidence of naturally-occurring antibodies to non-albicans 
Candida in NHS, although their abundance and complement fixation capacity may be limited 
[122]. However, Candida have acquired complement evasion mechanisms – several species bind 
factor H [123, 124], a host-expressed complement mediator normally involved in restricting 
alternative pathway activation such that host cells are spared. It accelerates the breakdown of the 
alternative pathway C3 convertase and serves as a cofactor of factor I, which cleaves the C3b 
opsonin to the inactive form iC3b [42]. In addition, C. albicans secretes proteases that degrade 
bound C3b and C4b [123] and the MAC may not be able to penetrate the fungal cell wall [121]. 
Yet complement is still required in clearance [125], perhaps by prompting downstream adaptive 
responses [126]. Fluconazole-resistant C. albicans and C. glabrata do show sensitivity to 
polymyxin B in combination with antifungals in vitro [127, 128]. Given that magainin 2 - an 
antibiotic unrelated to polymyxin B but mechanistically similar - is also both antifungal and 
synergistic with fluconazole, polymyxin B may act to destabilize the cell wall, as with bacteria 
[129]. In this way, antifungal use is obviated, with the particle platform targeted to specific 
Candida via monoclonal antibodies to conserved cell wall components such as mannan and 
glucans – both incite complement [130]. At the time of writing, it appears a complement 
modulating approach to sensitized Candida has not been attempted. A further benefit to this 
approach is that horizontal gene transfer from bacteria to eukaryotic Candida such as that 
conferring polymyxin resistance is exceedingly rare [131].                   
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CHAPTER 5: CONCLUSION 
 This work demonstrates that although there is minimal if any benefit in the mixed, 
targeted strategy utilizing the current crosslinker to orient the targeting antibody, cytotoxicity can 
be improved somewhat for the complement-resistant and clinically relevant O157 strain via 
nonspecific adsorption of its targeting antibody, whereas the complement-sensitive J5 is most 
susceptible to maximized polyclonal antibody coverage. However, this effect is insufficient to be 
clinically relevant, where by convention at least a tenfold improvement in cytotoxicity is sought. 
With modifications for clinical use and a more thorough understanding of how the two IgG types 
arrange and interact to maximize cytotoxicity with minimized loss of selectivity and 
anaphylatoxin release, the platform could be used as a first-line sensitizer to be combined with 
antibiotics or antibacterial peptides to slow the development of further antibiotic resistance.  
 
CHAPTER 6: FUTURE DIRECTIONS AND RECOMMENDATIONS 
 There are several measures that should be considered in the near-term to optimize the 
current platform, with insights then extrapolated to a more clinically-translatable version. As 
previously mentioned, better quality control in plating is required, as results may be highly 
variable and counterintuitive. With deviation cut-offs determined from further repetitions and/or 
existing literature, trends may be more consistent. Given that plating experiments were always 
conducted at a 5:1 particles: bacteria ratio, constructing dosing curves would be valuable to 
illustrate whether the UT and MT improve upon the performance of the MUT, and if so whether 
the doses are reasonable for in vivo translation. While the TCC ELISA provided interesting 
information towards the design of particles that maximize TCC formation in the supernatant 
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rather than at the particle surface, this should be viewed in the context of other central 
complement mediators, namely C1q, C3b, and C5a. Lastly, although serum from the same source 
was used for all cytotoxicity experiments, it should be evaluated for any antibody contamination 
(ex. passing through a Protein A/G column) or existing properdin.    
 The relationship between the proportions of each antibody and cytotoxicity, selectivity, 
and any influence in sepsis progression must be elucidated. Perhaps the 1x saturation of each IgG 
(so-called 2x particles) is most cytotoxic while retaining selectivity, yet results in substantial C5a 
release into the supernatant. Elevated serum C5a and other anaphylatoxins such as C3a and C4a 
often suggest a loss of complement homeostatic control and a more serious prognosis  [102, 
132]. We have demonstrated that the non-oriented anti-BSA can sequester C5a from serum [33], 
but this needs to be evaluated for particles with the inclusion of the monoclonal targeting 
antibodies and/or the NH2-PEG-biotin. Further, the targeting capability of the MT should be re-
assessed with NH2-PEG-biotin rheology to determine if a stiffer or more pliant crosslinker is 
suitable. The hydrodynamic character and radius of gyration of the crosslinker, if used, as well as 
the spacing and density of the carboxyl groups for the most effectual protein adsorption patterns 
must be determined to inform improved particle designs. Although protein adsorption to solid 
surfaces is non-uniform, the kinetics of adsorption is also affected by surface charge density [82], 
and this was not considered in the manufacturer’s equations to determine protein amounts 
needed for surface saturation. To investigate both the rheology of the crosslinker as well as 
changes in molecular spacing on the particle surface across particle types and IgG saturation 
extents, atomic force microscopy (AFM) could be utilized. The Sulchek lab has considerable 
expertise with this tool, and we have used it previously to probe the surface of UT particles [33].  
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 Complement fixation can be enhanced both by changing the class of the prompting IgG. 
IgG was selected in this study due to its ubiquitous commercial availability and previous 
characterization in our laboratory with the carboxylated particle base [33, 50, 52]. IgG is 
composed of four classes (IgG1-4), ordered by decreasing relative abundance in sera [84]. C1q 
binds more effectively to IgG1 and IgG3 than IgG2 and IgG4 [84], and the deposition extent of 
downstream complement mediators may vary by class as well [133]. The anti-BSA IgG used 
currently is polyclonal, consisting of a heterogenous mixture of IgG of various classes, and as 
such is subject to greater batch-to-batch variability. By utilizing a ‘dummy’ monoclonal 
activating IgG1 or IgG3, all originate from the same hybridoma clone and are therefore of the 
same class. A sought response could be more reliably engineered, although cost may be 
prohibitive. As complement-mediated damage to bystander cells is unavoidable given the 
nonspecific nature of the response, future work should select the complement-fixing IgG 
subclass that balances cytotoxicity with limited off-target effects. IgG spacing has also been 
shown to critically affect C1 complex avidity – IgG binding antigen on a surface may interact to 
form hexamers such that C1q may bind [26]. Thus far we have labeled the particles via passive 
adsorption, noting the highest complement activation and cytotoxicity without a preceding 
antigen layer [33]. However, this could be reevaluated in comparison to similar particles of a 
carboxyl density amenable to IgG spacing for hexamerization, with the antigen previously bound 
via EDC/NHS, for example. An approximate amount of IgG to add for this configuration could 
be estimated by attaining surface profiles via atomic force microscopy with varying extents of 
IgG coverage. MBL and ficolins (of the lectin pathway) may be useful, as well as engineered 
fusions of these [134].  
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 IgG class selection may also affect the uptake of the particle-bound bacteria complex at 
the infection site. Upon binding anaphylatoxins released during the cascade (particularly C5a), 
neutrophils are attracted and bind the Fc region of IgG via the FcγRIIIb [84], and once 
additionally bound to opsonins (C3b, iC3b, C4b) via CR3 (complement receptor 3), initiate 
phagocytosis [135]. IgG1- and IgG3-labeled particles are taken up more effectively than those 
bound with IgG2 and IgG4, but the strongest preference is for IgG3 [136].  
 In addition to or instead of the selection of the most advantageous IgG class, changing 
particle chemical composition could also augment complement, as well as aim the platform 
toward clinical feasibility. Complement mediators may directly bind to chemical functionalities 
and initiate the alternative pathway, namely hydroxyl and carboxyl groups [42, 137]. Increasing 
carboxyl abundance was shown to also decrease avidity for Factor H binding, a component of the 
alternative pathway that catalyzes inactivation of surface-bound C3b [42]; C3b-spurred C5 
convertase formation might continue longer, which would improve cytotoxicity. Our base 
particles are extensively carboxylated (~ 4/nm2 [33]) and thus amenable to the alternative 
pathway, but are non-biodegradable, and at 1 µm may occlude finer capillaries. In addition, we 
have noted that smaller particles (.5 µm diameter) similarly conjugated with IgG activate the 
classical pathway more strongly [52]. However, there is likely a size cutoff where insufficient 
IgG to initiate complement is bound. Polymers or materials that degrade under normal or 
inflammatory physiological conditions will be utilized for further studies, particularly those that 
display a high number of functional groups (particularly nucleophilic groups such as amine [43, 
138], hydroxyl [41, 138], and carboxyl [42] for C3b binding/derivatization. The polysaccharide 
chitosan could be suitable, as it is biodegradable in vivo to innocuous byproducts, its degradation 
time can be tuned by various factors controlled during its synthesis [139], it is heavily aminated 
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and carboxylated and can be further modified [140-142]. Further, chitosan possesses innate 
antibacterial properties – although not yet completely understood, high molecular weight 
chitosan may bind and destabilize components of the Gram-negative bacterial wall as it is 
strongly hydrophilic composition and negatively charged [143]. Lower molecular weight 
chitosan, though also antibacterial, tends to be less effective [144, 145]. Ma et al. demonstrated 
wide-range cytotoxicity against antibiotic resistant microbes with chitosan microparticles, which 
were unable to acquire resistance [146]. However, selectivity was not evaluated. Given that 
chitosan innately binds bacterial membranes and therefore complicates specificity in targeting, a 
chitosan coating of a degradable particle could be used as an adjuvant to spur complement with 
the coating Fc-conjugated to allow for targeting. Other materials of interest include carboxyl-
terminated PEG-PLGA (poly(lactic-co-glycolic acid) and triblock-copolymer Pluronic F127 
(polyethylene glycol – polypropylene glycol – polyethylene glycol). Both readily form micelles 
[147, 148]. Diblock carboxyl PEG-PLGA micelles form with the hydrophobic PLGA chains 
oriented inwards in aqueous environments, and carboxyl PEG chains oriented outwards [149]; a 
number of these carboxyl groups could be IgG-conjugated for targeting. The arrangement of the 
blocks can be modified to slow the hydrolysis of the ester linkages in the PLGA, extending 
circulation time [150]. Given that PEG characteristically inhibits opsonization, intermolecular 
spacing between PEG molecules on the particle surface as well as their surface density must be 
carefully analyzed given the synthesis conditions to preserve complement activation [151].  
Should smaller particles be utilized to improve complement response, bare carboxyl-terminated 
PLGA might be more suitable to better prevent cell uptake [150]. Carboxyl-terminated Pluronic 
F127 can allow for derivatization of constituent micelles with peptides and other thiol-containing 
biomolecules via pyridyl disulfide modification [152]. The polypropylene glycol core block 
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degrades with exposure to oxidizing species [42, 152], such as those released during respiratory 
burst of neutrophils or macrophages. There is also evidence that amplification of the alternative 
pathway is also facilitated by infiltrating neutrophils in a positive feedback loop mediated by 
neutrophil deposition of properdin upon bystander cells [153]. To further stimulate neutrophils, 
slowly-degrading micelles of carboxyl-PEG-PLGA or carboxyl-terminated Pluronic F127 could 
encapsulate hydrophobic immunostimulatory molecules such as the potent neutrophil 
chemoattractant peptide N-Formylmethionyl-leucyl-phenylalanine (fMLP) and/or superoxide 
inducer phorbol myristate acetate (PMA) [153]. To avoid severe complications, this would be 
contraindicated for sepsis. Morphological modifications can also be made to improve neutrophil 
uptake; particles with extensive microtexture can speed neutrophil recruitment and uptake in 
addition to increasing inflammasome activation [154].        
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